Clinical Trials Logo

Clinical Trial Summary

The primary purpose of the protocol is to demonstrate that the use of music therapy may make it possible to discontinue at least one of neuroleptic treatment in patients with AD or related symptoms complicated by behavioral disorders such as agitation and aggressiveness evaluated using the Neuropsychiatric Inventory (NPI).

The study hypothesis is that music therapy may have a positive impact on patients with AD complicated by behavioral disorders by reducing the intensity of oppositional behaviour and aggressiveness and allowing a diminution of neuroleptic treatment.


Clinical Trial Description

A technique of receptive music therapy to induce relaxation has been developed in the university hospital of Montpellier: the "U" sequence. The musical sequence lasts 20 minutes and is made up of several phases that progressively induce a relaxed state in the patient. This effect is obtained by modulating the rhythm of the music, the orchestral formation, frequencies and volume. The phase of maximum relaxation is followed by a stimulating phase. These musical sequences have been specially designed by the music publishers Music Care©. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02020356
Study type Interventional
Source University Hospital, Toulouse
Contact
Status Terminated
Phase N/A
Start date April 2013
Completion date June 2015

See also
  Status Clinical Trial Phase
Completed NCT01972204 - Intensive Instruction on the Use of Aricept N/A
Completed NCT01404169 - A 24-weeks, Multi-center, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Donepezil Hydrochloride in Chinese Subjects With Severe Alzheimer's Disease Phase 3
Recruiting NCT05397639 - Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type Phase 3
Completed NCT01539031 - Compare the Efficacy and Safety of Donepezil Hydrochloride 23 mg Treatment With Continuation of Donepezil Hydrochloride 10 mg Treatment in Japanese Subjects With Severe Alzheimer's Disease Phase 3
Completed NCT01276353 - A Study Versus E2020 10mg Followed by an Open-label Extension Phase to Explore the Safety of E2020 SR 23 mg in Japanese Subjects With Severe Alzheimer's Type Dementia Phase 2
Completed NCT03732053 - The Effectiveness of Global Postural Reeducation on Alzheimer Disease Patients N/A